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Differential protein expression of 
DARPP-32 versus Calcineurin in 
the prefrontal cortex and nucleus 
accumbens in schizophrenia and 
bipolar disorder
Yasuto Kunii1,2,7*, Mizuki Hino  1,7, Junya Matsumoto  1, Atsuko Nagaoka1, Hiroyuki Nawa3, 
Akiyoshi Kakita4, Hiroyasu Akatsu5,6, Yoshio Hashizume6 & Hirooki Yabe1
Dopamine- and cAMP-regulated phosphoprotein of molecular weight 32 kDa (DARPP-32) integrates 
dopaminergic signaling into that of several other neurotransmitters. Calcineurin (CaN), located 
downstream of dopaminergic pathways, inactivates DARPP-32 by dephosphorylation. Despite several 
studies have examined their expression levels of gene and protein in postmortem patients’ brains, 
they rendered inconsistent results. In this study, protein expression levels of DARPP-32 and CaN were 
measured by enzyme-linked immunosorbent assay (ELISA) in the prefrontal cortex (PFC), and nucleus 
accumbens (NAc) of 49 postmortem samples from subjects with schizophrenia, bipolar disorder, and 
normal controls. We also examined the association between this expression and genetic variants of 
8 dopaminergic system-associated molecules for 55 SNPs in the same postmortem samples. In the 
PFC of patients with schizophrenia, levels of DARPP-32 were significantly decreased, while those of 
CaN tended to increase. In the NAc, both of DARPP-32 and CaN showed no significant alternations in 
patients with schizophrenia or bipolar disorder. Further analysis of the correlation of DARPP-32 and CaN 
expressions, we found that positive correlations in controls and schizophrenia in PFC, and schizophrenia 
in NAc. In PFC, the expression ratio of DARPP-32/CaN were significantly lower in schizophrenia than 
controls. We also found that several of the aforementioned SNPs may predict protein expression, one 
of which was confirmed in a second independent sample set. This differential expression of DARPP-32 
and CaN may reflect potential molecular mechanisms underlying the pathogenesis of schizophrenia and 
bipolar disorder, or differences between these two major psychiatric diseases.
Dopamine- and cAMP-regulated phosphoprotein of molecular weight 32 kDa (DARPP-32), also known as phos-
phoprotein phosphatase-1 regulatory subunit 1B (PPP1R1B), is a key molecule that integrates dopaminergic 
signaling into that of several other neurotransmitters, such as a glutamate1. Phosphorylated DARPP-32 regulates 
the physiological activities of various proteins2. Calcineurin (CaN) is located downstream of dopaminergic and 
glutamatergic signaling and inactivates DARPP-32 by dephosphorylation3. CaN has also been associated with 
synaptic plasticity4 and neural cell apoptosis5. It has been reported that the CaN inhibitor tacrolimus induces 
psychotic side effects such as hallucinations, anxiety, paranoid delusions, dissociative fugues, and manic-like 
psychosis6–8. Therefore, elucidating the signaling pathway that involves DARPP-32 and CaN may be critical to 
understanding schizophrenia and other psychiatric disorders.
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Several studies have examined the expression of DARPP-32 in the postmortem prefrontal cortex (PFC) of 
patients with schizophrenia or bipolar disorder9–14, but only a few focused on other brain regions12,13,15–17. Besides, 
scarce reports have addressed the protein or mRNA expression of CaN in postmortem brains of patients with 
schizophrenia18,19, and no studies have investigated this expression in patients with bipolar disorder. DARPP-32 
and CaN are mostly expressed on dopamine receptor-positive neurons in various brain regions, especially in the 
caudate, putamen, and nucleus accumbens (NAc)20,21. In addition, NAc is an important contributor to the patho-
genesis of schizophrenia22; it has been especially implicated in generating so-called positive symptoms, such as 
delusions or hallucinations, on account of its major role in regulating dopamine release and midbrain dopamine 
system23. Nonetheless, the expression of DARPP-32 or CaN in the postmortem NAc of the patients with schizo-
phrenia has not been investigated. Thus, we investigated the expression of DARPP-32 and CaN in NAc and PFC 
of the patients with schizophrenia.
Meanwhile, numerous studies have attempted, without success, to replicate previously reported genetic asso-
ciations of multiple candidate genes with schizophrenia. Therefore, in recent years, most researchers have exten-
sively investigated the functional correlations between schizophrenia risk alleles and intermediate phenotypes 
using neuroimaging, and cognitive and neurophysiologic indexes. Kleinman et al. (2011) proposed “genetic neu-
ropathology,” a novel strategy in which the expression of mRNA and proteins in postmortem brains is used as 
ultimate intermediate phenotypes. They hypothesized that insights into the mechanisms of psychiatric diseases 
and identification of novel therapeutic targets will emerge from the association of genetic variations with relevant 
molecular phenotypes in postmortem brains24. Actually, several recent postmortem studies25–28, including our 
own16,29, have adopted this strategy and provided unique insights into genetic and molecular mechanisms under-
lying schizophrenia.
Therefore, in this study, we investigated the expression levels of DARPP-32 and CaN proteins in PFC and NAc, 
regions that receive dopaminergic input and are considered to be affected in schizophrenia. This analysis was 
performed in 49 postmortem samples from subjects with schizophrenia, bipolar disorder, and control subjects 
(Table 1) using enzyme-linked immunosorbent assay (ELISA). Moreover, we analyzed the associations between 
this expression and genetic variants of dopaminergic signaling-associated molecules for 55 single nucleotide pol-
ymorphisms (SNPs) in a much larger set of postmortem samples to examine the potential involvement of genetic 
variants in the pathophysiology of schizophrenia and bipolar disorder.
Results
Expression of DARPP-32 and Calcineurin in the diagnostic groups. In the PFC, we found that the 
expression levels of DARPP-32 evinced a significant decrease in patients with schizophrenia relative to controls 
(t (40.14) = 2.12, p = 0.040) (Fig. 1a) and that the expression of CaN tended to increase in patients with schizo-
phrenia (t (40.72) = 1.97, p = 0.056) as compared with controls; the mean of CaN expression in 6 patients with 
bipolar disorder was higher than that of controls (Fig. 2a). In the NAc, the expression levels of DARPP-32 and 
CaN showed no significant differences in schizophrenia patients relative to controls (t [23.14] = 1.54, p = 0.138; 
and t [34.16] = 1.56, p = 0.127; respectively; Figs 1b and 2b); by contrast, each mean of two protein expressions in 
bipolar patients were higher than that of controls respectively (Figs 1b and 2b).
We also assessed whether the expression level of either DARPP-32 or CaN in patients with schizophrenia was 
correlated with the daily dosage of antipsychotics that was prescribed in the 3 months immediately preceding 
each death. There were no significant effects of antipsychotic medication on the expression level of any of these 
proteins in any brain region examined (all p values > 0.5).
Further we assessed the correlation of expression levels of DARPP-32 and CaN in PFC and NAc (Fig. 3). 
Positive correlations were observed between the expression levels of DARPP-32 and CaN of controls in PFC 
(r = 0.585, p = 0.004) (Fig. 3a), patients with schizophrenia in PFC (r = 0.645, p = 0.002) (Fig. 3a) and NAc 
Schizophrenia
Bipolar 
Disorder Control Cont vs Sz (p value)
First sample set
Number of samples 21 6 22 —
Sex (M/F) 13/8 3/3 14/8 χ2-test p = 0.907
Mean age at death (year) 68.9 66.0 63.7 Welch’s t-test p = 0.195
Mean PMI (h) 16.1 17.0 14.7 Welch’s t-test p = 0.770
Mean CP-eq (mg/day) 653.5 — — —
Second sample set
Schizophrenia Others Control
Number of samples 2 6 26
Sex (M/F) 1/1 4/2 12/14
Mean age at death (year) 72 70.8 85.8
Mean PMI (h) 20.7 4.3 9.6
Mean CP-eq (mg/day) 1012.5 — —
Table 1. Characteristics of postmortem brain samples. First sample set was used protein expression study 
in diagnostic groups as well as genotyping. Second sample set was used to confirm the association between 
rs1801028 and protein expression. PMI, postmortem interval; CP eq, chlorpromazine equivalent dose.
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(r = 0.550, p = 0.010) (Fig. 3c). The ratio of these two proteins in each sample were compared between the diag-
nostic groups (Fig. 3b,d). In PFC, the ratio of DARPP-32/CaN in each sample were significantly low in schizo-
phrenia patients compared to controls (t [29.72] = 4.45, p = 1.12e-4) (Fig. 3b), but no changes were observed in 
NAc (t [33.71] = −0.185, p = 0.854) (Fig. 3d).
Effects of dopaminergic system associated molecules genotype on expression of DARPP-
32 and calcineurin. We examined the effects of 55 SNPs in 8 dopaminergic system associated molecules 
(ANKK1, DRD2, PPP1R1B, PPP3CA, PPP3CB, PPP3CC, PPP3R1, and PPP3R2) on the protein expression levels of 
DARPP-32 or CaN in a cohort of patients and controls (Table 1) as described in Materials and Methods. The levels 
of protein expression were compared between minor allele carriers and non-carriers of these SNPs. The results are 
summarized in Table 2a. Significant associations were observed with 4 SNPs in the DRD2 (2), PPP3CB (1), and 
PPP3CC (1). These SNPs predicted protein expression (DARPP-32 or CaN) in the postmortem brains (BA10 or 
NAc). As shown in Table 2b, analysis of a second independent sample set confirmed only 1 SNPs out of 4SNPs: 
exm956405 (=rs1801028). There was a significant association between the expressions of CaN in the NAc and 
exm956405 (Fig. 4; first sample set: U = 10.0, p = 0.016; second sample set: U = 0.0, p = 0.046).
Discussion
Our study is the first analysis of DARPP-32 protein expression levels in the NAc of the patients with schizophre-
nia and those of CaN in the postmortem brain tissue of the patients with bipolar disorder. We showed that the 
levels of DARPP-32 in the PFC of the patients with schizophrenia significantly decreased, while those of CaN 
tended to increase in the PFC of the patients with schizophrenia. On the other hand, levels of DARPP-32 and CaN 






























































Figure 1. Expression of DARPP-32 in the diagnostic groups. DARPP-32 expression in the BA10 (a) and NAc 
(b) of the control group (Cont), the group of patients with bipolar disorder, and the group of patients with 
schizophrenia (SZ); ELISA was used to measure protein expression. Error bars indicate the standard error of 
the mean (SEM). p value between controls and schizophrenia was calculated using the Weich’s t-test. Bipolar 



















































Figure 2. Expression of calcineurin in the diagnostic groups. Calcineurin (CaN) expression in the BA10 (a) 
and NAc (b) of the control group (Cont), the group of patients with bipolar disorder, and the group of patients 
with schizophrenia (SZ); ELISA was used to measure protein expression. Error bars indicate the standard error 
of the mean (SEM). p value between controls and schizophrenia was calculated using Weich’s t-test. Bipolar 
disorder was shown as a reference.
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the PFC we found that positive correlations between expressions of DARPP-32 and CaN and the expression ratio 
of DARPP-32/CaN were significantly lower in schizophrenia than controls. As aforementioned, the expression of 
DARPP-32 in the postmortem brain of patients with schizophrenia or bipolar disorder has been largely investi-
gated. While the levels of DARPP-32 protein in the PFC were decreased in patients with schizophrenia and bipo-
lar disorder9,11,12, findings relevant to the mRNA levels in these regions were inconsistent across studies10,13,14,30,31. 
Alternatively, a few studies have investigated postmortem expression of CaN in the brains of the patients with 
schizophrenia18,19,32–34, but no studies have analyzed this expression in bipolar disorder. These postmortem stud-
ies of DARPP-32 or CaN in schizophrenia and/or bipolar disorder are summarized in Table 3. Anyway, the most 
interesting findings in this study was that in the PFC there were positive correlations between DARPP-32 and 
CaN expression, and lower DARPP-32/CaN ratio in schizophrenia, which were firstly reported to the best of our 
knowledge. We could point out several suggestions from these results: (1) DARPP-32 and CaN were usually coex-
istent in the brain, even if in schizophrenia, (2) the balance between DARPP-32 and CaN was greatly disrupted 
in schizophrenia, and (3) these ware consistent with the results of the above previous postmortem studies review.
If decreased DARPP-32/CaN expression ratio is the primary pathophysiological alteration in the patients 
with schizophrenia, that means that upregulation of CaN promotes the inactivation of DARPP-3235. Decreased 
DARPP-32 activity induces a reduction in dopaminergic signaling in the PFC, which results in a so-called “hypof-
rontality” in schizophrenia. It is possible that a decrease in DARPP-32 expression in the PFC observed both in 
the current as well as in previous studies results, at least in part, from this process. On the contrary, it is of interest 
that the changes in CaN expression in the NAc evinced opposite tendencies in patients with schizophrenia and 


























































































































Figure 3. The correlation of the expression levels of DARPP-32 and CaN of control group and patients with 
schizophrenia. The expression levels of DARPP-32 and CaN in PFC (a) and NAc (c) of control group (closed 
circles) and patients with schizophrenia (open circles) are shown by scatter plots. The ratio of DARPP-32 and 
CaN expression of each sample were compared between diagnostic groups in PFC (b) and NAc (d). The p values 
between controls and schizophrenia were calculated using Welch’s t-test. Error bars indicate SEM.
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dephosphorylation, it can be concluded that CaN exerts a buffering action against excessive dopamine signaling. 
It is probable that variations in CaN expression may reflect different dopaminergic pathologies between these two 
major psychiatric diseases.
We also found that several SNPs of the gene encoding DRD2 and CaN were associated with DARPP-32 or 
CaN protein expression in postmortem brains. In particular, the polymorphism of protein phosphatase 3 cata-
lytic subunit gamma (PPP3CC), a gene encoding the CaN γ-catalytic subunit, was previously found to be relevant 
to schizophrenia. Genetic studies revealed a significant association between genetic variations of PPP3CC36 or 
PPP3CC gene haplotype37 and the incidence of schizophrenia; however, no correlations were found for other 
population samples38–40. In addition, an association between the PPP3CC gene and bipolar disorder was also 
reported41. Another study using forebrain-specific PPP3CC gene-knockout mice reported multiple abnormal 
behaviors associated with schizophrenia, such as decreased social interaction and impairments in prepulse 
inhibition42.
In a second independent sample set, we could confirm only 1 SNP, exm956405 (=rs1801028), that predicted 
CaN expression in the NAc. This SNP was identified as a novel missense nucleotide change causing an amino 
acid substitution of serine with cysteine at codon 311 (Ser311Cys) in DRD243. An association study showed that 

























(a) First sample set
DRD2 exm956405 (=rs1801028) exonic, Ser ⇒ Cys CaN NAc 3/42 (10.2, 0.001) 0.55 (C+/C−) 0.016
DRD2 exm956405 (=rs1801028) exonic, Ser ⇒ Cys CaN BA10 3/45 (11.0, 0.001) 1.78 (C+/C−) 0.023
DRD2 rs2734833 intronic DARPP NAc 3/41 (44.0, 0) 0.67 (T+/T−) 0.043
PPP3CB exm2259632 (=rs 12644) exonic DARPP BA10 34/14 (1.92, 0.166) 1.35 (T+/T−) 0.015
PPP3CC rs1116084 intronic DARPP BA10 37/11 (0.756, 0.385) 1.68 (A+/A−) 0.016















DRD2 exm956405 (=rs1801028) exonic, Ser ⇒ Cys CaN NAc 2/6 (8, 0.0047) 0.37 (C+/C−) 0.046









































Figure 4. The allelic effect of exm956405 (=rs1801028) on the expression of calcineurin. A significant 
association was detected between the expression of CaN in the NAc and exm956405. The p-value between these 
groups was calculated using the Mann-Whitney U-test.
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patients with schizophrenia that exhibited the Cys311 allele spent less time sin the hospital, presented less severe 
negative symptoms, and were more often married compared to patients without Cys31144. These results suggest 
that patients with schizophrenia that have the Cys311 allele may respond well to antipsychotic treatment and, as a 
result, shows relatively mild negative symptoms. A several meta-analyses also demonstrated this association45–47. 
The tendency of this association was observed in our samples of this study (relative risk; 2.968, Fisher’s exact test; 
p = 0.071). It was further demonstrated that dopamine-induced internalization of DRD2 was impaired in the 
Cys311 variant of DRD248. Since the internalization of DRD2 contributes to its desensitization49, the desensitiza-
tion of DRD2 may also be suppressed in patients with the Cys311 variant. Thus, the disturbance of DRD2 desen-
sitization can prolong dopamine-induced DRD2-mediated signaling and accelerate the subsequent processes 
(Fig. 5). Eventually, dephosphorylation of cAMP response element-binding protein (CREB) binds upstream of 
four CaN genes (PPP3CA, PPP3CB, PPP3CC, PPP3R1; found through the ChIP-Atlas database at “chip-atlas.
org”) and then decreases CaN expression. This assumed mechanism (Fig. 5) was consistent with our finding that 
subjects with Cys311 in DRD2 featured lower levels of CaN in the NAc (Fig. 4). In other words, the C allele of 
rs1801028 was at risk for schizophrenia and was associated with lower CaN expression in the NAc.
The present study performed on brain samples has several limitations that require further attention. First, con-
founding effects of disease-related factors including medication may have affected the expression of DARPP-32, 
CaN, or both. Although we did not observe any effects of antipsychotic drugs on the levels of DARPP-32 or CaN 
expression in this study, additional animal studies are necessary to investigate the effects of chronic antipsychotic 
administration on the expression of these proteins in the PFC and NAc. Second, our study population was rela-
tively small, especially for a genetic study. In addition, we could not uniformly sample from group with sufficient 
equilibrium because the NAc was a relatively small area and there were a small number of NAc available. As a 
result, several genotypes in this study including rs1801028 were not two in Hardy–Weinberg Equilibrium. The 
findings must be, therefore, confirmed via postmortem examination of a larger brain cohort.
In conclusion, our results show that the expressions of the DARPP-32 and CaN protein were altered in post-
mortem brains of the patients with schizophrenia and bipolar disorder compared to those from control subjects, 
which is accompanied by genetic variations. Our results may reflect potential molecular mechanisms underly-
ing the pathogenesis of schizophrenia and bipolar disorder or differences between these two major psychiatric 
diseases.
Number of resources Brain Region Taget molecule Method Main findings Refference
(a) Postmortem brain studies of DARPP-32
SZ(14), CONT(14) PFC Protein Immunoblot DARPP-32 expression was reduced in SZ Albert et al.9
SZ(12), BP(10), CONT(11) PFC Protein IHC, Immunoblot DARPP-32 expression was lower in SZ and BP Ishikawa et al.11
SZ(9), CONT(9) PFC, Hip, Striatum Protein IHC
DARPP-32 immnoreactive neurons were lower in 
layers II-V of PFC in SZ Kunii et al.
12
SZ(11), CONT(10) Insula cortex Protein IHC DARPP-32 immnoreactive neurons were lower in layers II-III of inslula in SZ Nishiura et al.
17
SZ(11), CONT(11) STG Protein IHC DARPP-32 immnoreactive neurons were lower in layers III-IV of STG in SZ Kunii et al.
15
SZ(12), CONT(12) Striatum Protein Immunoblot DARPP-32 expression was increased in CAU of SZ Kunii et al.16
SZ(13), CONT(8) Thalamus mRNA ISH No chnages in DARPP-32 mRNA expression in thalamic nuclei of SZ Clinton et al.
31
SZ(18), CONT(11) PFC, ACC mRNA ISH No chnages in DARPP-32 mRNA expression in PFC and ACC of SZ Baracskay et al.
10
SZ(35), BP(35), CONT(35) PFC mRNA Realtime PCR DARPP-32 mRNA expression was reduced in PFC of SZ who died by suicide Feldcamp et al.
30
SZ(33), BP(32), CONT(34) PFC mRNA Realtime PCR DARPP-32 mRNA expression was increased in PFC of SZ and BP Zhan et al.
14
SZ (n = 176), BP (n = 61), 
MDD(138)CONT 
(n = 283)
PFC, Hip, Cau mRNA Realtime PCR t-DARPP mRNA expression was increased in PFC of SZ and BP Kunii et al.
13
(b) Postmortem brain studies of CaN
Number of resources Brain Region Taget molecule Method Main findings Refference
SZ(15), CONT(15) PFC, Hip Protein Immunoblot No chnages in CaN in PFC and Hip of SZ Kozlovsky et al.19
SZ(9), CONT(9) PFC, Hip, Striatum Protein IHC
CaN immnoreactive neurons were increased in 
caudate of SZ Wada et al.
33
SZ(12), CONT(12) Striatum Protein Immunoblot No chnages in CaN in caudate and putamen of SZ Kunii et al.16
SZ(11), CONT(11) STG Protein IHC CaN immnoreactive neurons were increased in layers II-VI of STG in SZ Wada et al.
34
SZ(12), CONT(12) PFC mRNA DNA microarray (cDNA) CaN A mRNA was increased in PFC of SZ Hakak et al.
32
SZ(13), CONT(12) Hip Protein, mRNA ELISA, RT-PCR CaN A and mRNA were decreased in hip of SZ Eastwood et al.18
Table 3. Overview of postmortem brain studies focused on DARPP-32(a) and CaN(b). SZ, schizophrenia; 
CONT, control; BP, bipolar; PFC, prefrontal cortex; Hip, hippocampus; STG, superior temporal gyrus; ACC, 
anterior cingulate gyrus; Cau, caudate; IHC, immunohistochemistry; ISH, in situ hybridization; ELISA, 
enzyme-linked immunosorbent assay; CaN, calcineurin.
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Materials and Methods
Human postmortem brain tissue collection. Postmortem brain tissue samples from patients with schiz-
ophrenia, bipolar disorder, and control subjects were obtained from Fukushima Brain Bank at the Department of 
Neuropsychiatry, Fukushima Medical University; Brain Research Institute, Niigata University; and Choju Medical 
Institute Fukushimura Hospital, Toyohashi as described previously29. Use of postmortem human brain tissues for 
the present study was approved by the Ethics Committee of Fukushima Medical University and Niigata University, 
and complied with the Declaration of Helsinki and its later amendments. All procedures were carried out with the 
informed written consent of the next of kin. Detailed demographic information of brain tissues from 21 subjects 
with schizophrenia, 6 subjects with bipolar disorder and 22 control subjects used in this study (it was identical to 
first sample set in genotyping) was summarized in Table 1. Each patient with schizophrenia and bipolar disorder ful-
filled the diagnostic criteria established by the American Psychiatric Association (Diagnostic and Statistical Manual 
of Mental Disorders: DSM-IV). For patients with schizophrenia, the daily dosage of antipsychotics prescribed dur-
ing the 3 months immediately preceding death is shown as chlorpromazine-equivalent dose (mg/day, Table 1).
DNA collection and SNP genotyping. The subjects for the association analysis between SNPs and protein 
expression consisted of 27 patients (16 men; mean age, 68.2 ± 15.2 years) and 22 control subjects (14 men; mean 
age, 63.7 ± 14.4 years). A second replication sample set consisted of 34 subjects (17 men; mean age, 82.4 ± 9.4 
years). Genomic DNA was extracted from the frozen cerebellum or occipital cortex and genotyping was per-
formed using HumanCoreExome −24 v1.0 Beadchip on an iScan system (Illumina, Tokyo, Japan) as described 
previously29. Of 128 SNPs derived from 8 dopaminergic system-associated genes [Ankyrin repeat and kinase 
domain containing 1(ANKK1), dopamine D2 receptor (DRD2), phosphoprotein phosphatase-1 regulatory subu-
nit 1B(PPP1R1B), protein phosphatase 3 catalytic subunit alpha (PPP3CA), protein phosphatase 3 catalytic subu-
nit beta (PPP3CB), protein phosphatase 3 catalytic subunit gamma (PPP3CC), protein phosphatase 3 regulatory 
subunit B alpha (PPP3R1), and protein phosphatase 3 regulatory subunit B beta (PPP3R2)] included in the chip, 
we excluded SNPs with call rates of <95% and minor allele frequencies of <1%; the number of SNPs analyzed 
thus totaled to 55 (Supplementary Table S1).
Tissue retrieval and processing for ELISA. Pieces (weighing approximately 100 mg) of gray matter tissue 
from Brodmann area 10 (BA10) as PFC and NAc were isolated from frozen brain. For PFC, gray matter tissue 
was dissected from the frontal pole. NAc was identified on the frozen coronal slabs corresponding to the anterior 
one-third of the inferior temporal cortex. These frozen brain tissues were suspended in the 2% SDS solution, 
incubated for 20 min, subjected to three freeze-thaw cycles, and sonicated for 10 min. Then, the samples were 
diluted in phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4) so 
that the final concentration of SDS was below 0.2%. The expression of proteins was determined by using commer-
cial ELISA kits (SEB323Hu for Calcineurin, and SEE017Hu for DARPP-32, Cloud Clone Corp, Houston, TX). 
The analysis was performed according to the manufacturer’s protocols. The expression levels of each protein were 
normalized against the total protein concentration.
Statistical analysis. Demographic variables (sex, age, and PMI) were compared between the groups 
using a χ2-test and Welch’s t-test. The latter was also used for comparing the levels of protein (DARPP-32, 
CaN) expression between the diagnostic groups (schizophrenia and control, with bipolar disorder as a refer-
ence). The correlations of expression levels of DARPP-32 and CaN in each sample were assessed by Pearson’s 
correlation coefficients, and the ratio of proteins were compared between the diagnostic groups by Welch’s t-test. 
For association study of SNPs, we divided all samples into minor allele carriers and non-carriers of each SNPs. 
Impaired DA-induced internalizaon of DRD2
Increased DA-induced DRD2-mediated signaling
CaN acvaon by elevated intracellular Ca2+ level
PP1 acvaon through the dephosphorylaon of DARPP-32
Dephosphorylaon of CREB
Decreased CaN expression
Figure 5. Flow chart of the DARPP-32-CaN pathway in the Cys311 variant of DRD2. The disturbance of DRD2 
desensitization can prolong dopamine-induced DRD2-mediated signaling and accelerate the following processes; 
PLC activation, IP3 release, and Ca2+ release from the endoplasmic reticulum. As a result, increased intracellular 
Ca2+ activates CaN. The activated CaN can then promote PP1 activation through the dephosphorylation of 
DARPP-32. Dephosphorylation of CREB may then be promoted in the brains carrying the Cys311 variant of DRD2. 
Since the ChIP analysis showed that CREB binds upstream of several CaN genes, dephosphorylation of CREB may 
decrease CaN expression. DRD2, dopamine D2 receptor; PLC, phospholipase C; IP3, Inositol trisphosphate; CaN, 
calcineurin;PPI,;CREB, cAMP response element-binding protein; ChIP, Chromatin immunoprecipitation.
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A Mann-Whitney U-test was then used for comparing the levels of protein expression between the genotypes 
of each SNP. In the comparison between the two groups, we excluded outliers (>mean ± 3 SD) from analysis. 
Further, Spearman’s rank correlation coefficients were used to assess the association between the expressions 
of each protein and estimated total dosage of neuroleptic drugs. SPSS ver. 25.0 (SPSS, Chicago, IL, USA) and 
(SigmaPlot14.0; Systat Software Inc., San Jose, CA, USA) was used for analysis.
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